Chevy Chase Trust Holdings LLC Grows Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Chevy Chase Trust Holdings LLC boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 106.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,049 shares of the biotechnology company's stock after purchasing an additional 11,890 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of United Therapeutics worth $8,260,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Ascent Group LLC purchased a new position in United Therapeutics in the third quarter worth about $265,000. Erste Asset Management GmbH bought a new stake in United Therapeutics during the third quarter valued at approximately $16,224,000. Edgestream Partners L.P. purchased a new stake in United Therapeutics during the third quarter valued at approximately $1,584,000. Caisse DE Depot ET Placement DU Quebec raised its position in United Therapeutics by 32.5% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company's stock worth $123,181,000 after acquiring an additional 84,369 shares during the period. Finally, Captrust Financial Advisors boosted its stake in shares of United Therapeutics by 3.7% during the 3rd quarter. Captrust Financial Advisors now owns 3,452 shares of the biotechnology company's stock worth $1,237,000 after acquiring an additional 124 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent research reports. TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. LADENBURG THALM/SH SH raised their price target on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Argus upped their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Jefferies Financial Group increased their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Finally, HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Performance

UTHR stock traded down $4.70 during midday trading on Friday, reaching $369.67. The stock had a trading volume of 196,055 shares, compared to its average volume of 451,875. The firm has a fifty day simple moving average of $368.91 and a two-hundred day simple moving average of $337.96. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The stock has a market cap of $16.51 billion, a PE ratio of 16.45, a P/E/G ratio of 1.07 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.38 EPS. On average, sell-side analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 7,802 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the transaction, the chief financial officer now directly owns 3,210 shares of the company's stock, valued at $1,108,766.10. The trade was a 70.85 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 127,142 shares of company stock valued at $47,460,419. 11.90% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.